Largest demonstration of its kind combines leading hardware, platforms, and techniques to achieve 20 times speedup over previous demonstrations Ecosys...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...
Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...
-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on devel...
As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—espec...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by t...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a significant leadership transition with the appointment ...
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treat...
© 2025 Biopharma Boardroom. All Rights Reserved.
